General Applicability of Existing College of American Pathologists Accreditation Requirements to Clinical Implementation of Machine Learning-Based Methods in Molecular Oncology Testing.

Larissa V Furtado, Kenji Ikemura, Cagla Y Benkli, Joel T Moncur, Richard S P Huang, Ahmet Zehir, Katherine Stellato, Patricia Vasalos, Navid Sadri, Carlos J Suarez
{"title":"General Applicability of Existing College of American Pathologists Accreditation Requirements to Clinical Implementation of Machine Learning-Based Methods in Molecular Oncology Testing.","authors":"Larissa V Furtado, Kenji Ikemura, Cagla Y Benkli, Joel T Moncur, Richard S P Huang, Ahmet Zehir, Katherine Stellato, Patricia Vasalos, Navid Sadri, Carlos J Suarez","doi":"10.5858/arpa.2024-0037-CP","DOIUrl":null,"url":null,"abstract":"<p><strong>Context.—: </strong>The College of American Pathologists (CAP) accreditation requirements for clinical laboratory testing help ensure laboratories implement and maintain systems and processes that are associated with quality. Machine learning (ML)-based models share some features of conventional laboratory testing methods. Accreditation requirements that specifically address clinical laboratories' use of ML remain in the early stages of development.</p><p><strong>Objective.—: </strong>To identify relevant CAP accreditation requirements that may be applied to the clinical adoption of ML-based molecular oncology assays, and to provide examples of current and emerging ML applications in molecular oncology testing.</p><p><strong>Design.—: </strong>CAP accreditation checklists related to molecular pathology and general laboratory practices (Molecular Pathology, All Common and Laboratory General) were reviewed. Examples of checklist requirements that are generally applicable to validation, revalidation, quality management, infrastructure, and analytical procedures of ML-based molecular oncology assays were summarized. Instances of ML use in molecular oncology testing were assessed from literature review.</p><p><strong>Results.—: </strong>Components of the general CAP accreditation framework that exist for traditional molecular oncology assay validation and maintenance are also relevant for implementing ML-based tests in a clinical laboratory. Current and emerging applications of ML in molecular oncology testing include DNA methylation profiling for central nervous system tumor classification, variant calling, microsatellite instability testing, mutational signature analysis, and variant prediction from histopathology images.</p><p><strong>Conclusions.—: </strong>Currently, much of the ML activity in molecular oncology is within early clinical implementation. Despite specific considerations that apply to the adoption of ML-based methods, existing CAP requirements can serve as general guidelines for the clinical implementation of ML-based assays in molecular oncology testing.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of pathology & laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5858/arpa.2024-0037-CP","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Context.—: The College of American Pathologists (CAP) accreditation requirements for clinical laboratory testing help ensure laboratories implement and maintain systems and processes that are associated with quality. Machine learning (ML)-based models share some features of conventional laboratory testing methods. Accreditation requirements that specifically address clinical laboratories' use of ML remain in the early stages of development.

Objective.—: To identify relevant CAP accreditation requirements that may be applied to the clinical adoption of ML-based molecular oncology assays, and to provide examples of current and emerging ML applications in molecular oncology testing.

Design.—: CAP accreditation checklists related to molecular pathology and general laboratory practices (Molecular Pathology, All Common and Laboratory General) were reviewed. Examples of checklist requirements that are generally applicable to validation, revalidation, quality management, infrastructure, and analytical procedures of ML-based molecular oncology assays were summarized. Instances of ML use in molecular oncology testing were assessed from literature review.

Results.—: Components of the general CAP accreditation framework that exist for traditional molecular oncology assay validation and maintenance are also relevant for implementing ML-based tests in a clinical laboratory. Current and emerging applications of ML in molecular oncology testing include DNA methylation profiling for central nervous system tumor classification, variant calling, microsatellite instability testing, mutational signature analysis, and variant prediction from histopathology images.

Conclusions.—: Currently, much of the ML activity in molecular oncology is within early clinical implementation. Despite specific considerations that apply to the adoption of ML-based methods, existing CAP requirements can serve as general guidelines for the clinical implementation of ML-based assays in molecular oncology testing.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
现有美国病理学家学会认证要求对分子肿瘤学检测中基于机器学习方法的临床实施的一般适用性。
背景美国病理学家学会(CAP)对临床实验室检测的认证要求有助于确保实验室实施并维护与质量相关的系统和流程。基于机器学习(ML)的模型与传统的实验室检测方法有一些共同之处。专门针对临床实验室使用 ML 的认可要求仍处于早期发展阶段:确定可能适用于临床采用基于 ML 的分子肿瘤学检测方法的相关 CAP 认证要求,并提供分子肿瘤学检测中当前和新兴 ML 应用的实例:对与分子病理学和普通实验室实践(分子病理学、所有普通实验室和普通实验室)相关的 CAP 认证检查表进行了审查。总结了一般适用于基于分子生物学检测的分子肿瘤学检测的验证、再验证、质量管理、基础设施和分析程序的核对表要求实例。根据文献回顾评估了分子肿瘤学检测中使用 ML 的实例:结果--:CAP 一般认证框架中用于传统分子肿瘤学检测验证和维护的部分也适用于在临床实验室实施基于 ML 的检测。ML 在分子肿瘤学检测中的现有和新兴应用包括用于中枢神经系统肿瘤分类的 DNA 甲基化分析、变异调用、微卫星不稳定性检测、突变特征分析和组织病理学图像变异预测:目前,分子肿瘤学领域的大部分 ML 活动都处于早期临床实施阶段。尽管在采用基于 ML 的方法时有一些具体的考虑因素,但现有的 CAP 要求可以作为在分子肿瘤学检测中临床实施基于 ML 的检测方法的一般指导原则。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non-Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies. Ethical and Regulatory Perspectives on Generative Artificial Intelligence in Pathology. Reduced Plasma Selenoprotein P Is Associated With Type I Antithrombin Deficiency and a Prothrombotic State. The Anatomic Pathology Hospitalist Model. Histologic Features of Liver Injury Associated With SARS-CoV-2 Messenger RNA Vaccines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1